In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [68Ga]Annexin A5 and [18F]FDG PET
- 1 December 2014
- journal article
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 21 (6) , 1191-1199
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Erythropoietin and the heart: Physiological effects and the therapeutic perspectiveInternational Journal of Cardiology, 2014
- Regulation of erythropoiesis by hypoxia-inducible factorsBlood Reviews, 2013
- Migration of bone marrow‐derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarctionJournal of Cellular and Molecular Medicine, 2011
- Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survivalCardiovascular Research, 2007
- Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularizationEuropean Heart Journal, 2007
- Accurate noninvasive measurement of infarct size in mice with high-resolution PET.2006
- Incidence of stunned, hibernating and scarred myocardium in ischaemic cardiomyopathyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.2004
- Quantitative gated PET for the assessment of left ventricular function in small animals.2003
- Global and regional functional measurements with gated FDG PET in comparison with left ventriculographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001